German Health Minister Karl Lauterbach, has placed an emphasis on speeding up the process of legalizing cannabis for recreational use. He said in a press statement that he wants to put a bill to legalize cannabis for recreational use on the summer legislative agenda, instead of pushing it back to the fall.
If you want to find more details about the legalization of cannabis in Germany and to read the latest cannabis news from around the world, download for free the Hemp.im mobile app,
Lauterbach said he has changed his mind on the issue over the past two years
“I’ve always been opposed to cannabis legalization, but I changed my opinion about a year ago,” he said. He now believes that the dangers of outlawing cannabis outweigh the dangers of legalizing cannabis for adults.
Lauterbach’s statements on cannabis reform were part of his call for more action on several pressing issues facing the German healthcare system. Namely, the need for more input from German citizens to address the massive shortage of health insurers, as well as the digitization of healthcare infrastructure.
His comments also come at a time when all coalition parties are driving the narrative that the issue of marijuana legalization should no longer be swept under the rug. In the first quarter of 2022, despite the inclusion of marijuana legalization on the Traffic Light coalition’s election agenda, the only thing emanating from Berlin for several months were calls to delay the process. The excuse was both the prolonged pandemic and the Russian invasion of Ukraine.
Even more interesting is that Lauterbach’s comments came at a time when all three coalition partners were beginning to publicly support the idea of home-grown marijuana as part of the initial marijuana legalization bill.
Reasons for accelerating cannabis legalization
There are several reasons that are likely behind this turnaround by leading figures in the new government to suddenly prioritize cannabis law reform this year.
The first is undoubtedly that the medical efficacy of cannabis can no longer be denied. This means that insurance companies will be increasingly pressured to reform their coverage policies – and pay to insure more people.
This was one of the most problematic aspects of the medical cannabis compromise, which was legalized in 2017. Insurers routinely reject about 40 percent of medical cannabis reimbursement applicants. Patients who receive reimbursement cause losses for insurers, and those who do not receive reimbursement must use the black market.
Second, with the full legalization of cannabis for recreational use, patients who are rejected by insurance will at least no longer be criminalized for taking matters into their own hands.
Furthermore, if patients are finally allowed to grow their own cannabis at home, the pressure will be taken off a health care system that has been very sluggish to date.
As a result, after months of delays, there may finally be a push to legalize cannabis for adults, which could even happen this summer – at least at the legislative level.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in Fakty Konopne, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
The TopRanked.io Weekly Digest: What’s Hot in Affiliate Marketing [++ A2 Hosting Affiliates Review]
Something's brewing in the Right to Repair space. Lawmakers are increasingly law-making. DIY fixer upperers are increasingly fixer uppering. And,...
Why the Carbon Credit Market Is Not Working
The Carbon Brief analysis focused on 34 companies that alone used 38 million tons of carbon dioxide over the period...
Recrowd, Real Estate Lending Platform, Finally Gets European Authorization
Recrowd adopts a distinct approach for less sophisticated investors, limiting their investments to under €1,000 or 5% of their net...
Why the Amounts Invested in Belgian Fintech Companies Decreased
In 2023, the Belgian fintech sector has not witnessed any major fundraising events similar to those in previous years, such...
Bitcoin Soars 130% This Year: Will It Reach New All-Time Highs in 2024?
Bitcoin is currently trading within an ascending channel, maintaining support at $35,000, with an upward trajectory towards the psychological resistance...
Biotech1 week ago
Vive Biotech Contacts Santander to Find a Buyer
Impact Investing3 days ago
Hi-Tech Buoy to Clean Up the Seas Created by Jelter
Business2 weeks ago
When You Finally Understand the Rules Someone Always Changes Them
Biotech1 week ago
Novo Nordisk Invests €2.1 Billion in Its French Plant